Trastuzumab and Chemo Combo for Advanced Gastroesophageal Junction Cancer


TrastuzumabA study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell proliferation is regulated at different checkpoints. A defect in this protein may result in the uncontrolled proliferation of the cell resulting in tumour.  Trastuzumab is a humanized monoclonal antibody which help arrest the cell cycle at the G1 phase and hence the cell division. Trastuzumab binds to the HER2/neu receptor and exerts it effect by down regulating the HER2/neu receptor and arresting the cell cycle.

The participants were randomly assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in combination with intravenous Trastuzumab. The survival rate of patients on chemotherapy with Trastuzumab was slightly higher than those who were on chemotherapy alone. Additionally, the regimen with Trastuzumab did not increase the adverse effects most commonly associated with chemotherapeutic agents. Nausea and vomiting was not significantly higher in the patients given Trastuzumab than those in chemotherapeutic agents alone.

The propensity of the drug to increase survival rates without the additional adverse effects proves to be a promising breakthrough in gastroesophageal junction cancer research. However, since the results of the study emerged, limited data exists about the optimal duration of Trastuzumab therapy. Fortunately, the pharmaceutical field has not faltered in its quest to continually improve the optimal duration data profile of the drug. In order to facilitate these endeavors, LGM Pharma has made the supply of Trastuzumab CAS# 180288-69-1 to pharmaceutical companies a top priority. Currently, the company works in collaboration with GMP and ISO certified manufacturers in order to meet the growing demands for active pharmaceutical ingredients for research and development purposes.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:
One comment
  • Monoclonal Antibodies (mAb’s) – Growth, Supply, and Uses for Cancer Treatment « LGM Pharma Blog
    Posted on May 17, 2011 at 10:29 am

    […] Trastuzumab CAS# 180288-69-1 – Some of the most aggressive breast cancers (approx. 25% of primary breast cancers) are driven by overly expressed HER2 receptors – which cause the rapid progression of breast cancer. Trastuzumab targets these receptors both intercellularly (by inhibiting cell proliferation) and extracellularly (by flagging them for destruction by the immune system), effectively leading to HER2 positive tumor cell stasis and death. In addition, based on preclinical studies, Trastuzumab enhances the effects of chemotherapy. Read more about Trastuzumab here: Higher survival rates for Trastuzumab in combination with chemotherapy in advanced gastroesophageal …. […]

Comments are closed.